Stock Scorecard
Stock Summary for Aligos Therapeutics Inc (ALGS) - $10.45 as of 10/20/2025 4:59:10 PM EST
Total Score
11 out of 30
Safety Score
40 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ALGS
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ALGS
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ALGS
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for ALGS
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for ALGS (40 out of 100)
| Stock Price Rating (Max of 10) | 5 |
| Historical Stock Price Rating (Max of 10) | 10 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 6 |
| Book Value to Price (Max of 10) | 8 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 3 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for ALGS
Financial Details for ALGS
Company Overview |
|
|---|---|
| Ticker | ALGS |
| Company Name | Aligos Therapeutics Inc |
| Country | USA |
| Description | Aligos Therapeutics, Inc. (ALGS) is a dynamic clinical-stage biopharmaceutical company based in South San Francisco, California, focused on developing innovative therapies for viral infections and liver diseases. Its extensive pipeline features candidates for chronic hepatitis B and liver fibrosis, underscoring the company's commitment to addressing critical unmet medical needs through advanced scientific approaches and strategic collaborations. Aligos's dedication to pioneering transformative healthcare solutions positions it as a compelling investment opportunity for institutional investors seeking growth in the biopharmaceutical sector. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 10.45 |
| Price 4 Years Ago | 296.75 |
| Last Day Price Updated | 10/20/2025 4:59:10 PM EST |
| Last Day Volume | 72,809 |
| Average Daily Volume | 87,528 |
| 52-Week High | 46.80 |
| 52-Week Low | 3.76 |
| Last Price to 52 Week Low | 177.93% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 22.69 |
| Sector PE | 40.29 |
| 5-Year Average PE | -23.63 |
| Free Cash Flow Ratio | 3.43 |
| Industry Free Cash Flow Ratio | 14.62 |
| Sector Free Cash Flow Ratio | 29.76 |
| Current Ratio Most Recent Quarter | 6.31 |
| Total Cash Per Share | 3.05 |
| Book Value Per Share Most Recent Quarter | 16.56 |
| Price to Book Ratio | 0.70 |
| Industry Price to Book Ratio | 29.98 |
| Sector Price to Book Ratio | 32.15 |
| Price to Sales Ratio Twelve Trailing Months | 21.88 |
| Industry Price to Sales Ratio Twelve Trailing Months | 30.99 |
| Sector Price to Sales Ratio Twelve Trailing Months | 16.11 |
| Analyst Buy Ratings | 2 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 6,151,400 |
| Market Capitalization | 64,282,130 |
| Institutional Ownership | 54.14% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -49.65% |
| Reported EPS 12 Trailing Months | -13.27 |
| Reported EPS Past Year | -3.64 |
| Reported EPS Prior Year | -16.36 |
| Net Income Twelve Trailing Months | -74,184,000 |
| Net Income Past Year | -131,211,000 |
| Net Income Prior Year | -87,679,000 |
| Quarterly Revenue Growth YOY | -9.00% |
| 5-Year Revenue Growth | 354.81% |
| Operating Margin Twelve Trailing Months | -1,924.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 18,771,000 |
| Total Cash Past Year | 36,997,000 |
| Total Cash Prior Year | 135,704,000 |
| Net Cash Position Most Recent Quarter | 18,771,000 |
| Net Cash Position Past Year | 36,997,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 0.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | -28,973,000 |
| Total Stockholder Equity Prior Year | 92,080,000 |
| Total Stockholder Equity Most Recent Quarter | 101,866,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -75,123,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -12.21 |
| Free Cash Flow Past Year | -80,873,000 |
| Free Cash Flow Prior Year | -79,016,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | False |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.07 |
| MACD Signal | 0.05 |
| 20-Day Bollinger Lower Band | 6.60 |
| 20-Day Bollinger Middle Band | 9.08 |
| 20-Day Bollinger Upper Band | 11.55 |
| Beta | 2.77 |
| RSI | 52.40 |
| 50-Day SMA | 19.33 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 27.24 |
System |
|
| Modified | 10/20/2025 4:59:11 PM EST |